Literature DB >> 7514045

Inhibition of human B-cell lymphoma growth by CD40 stimulation.

S Funakoshi1, D L Longo, M Beckwith, D K Conley, G Tsarfaty, I Tsarfaty, R J Armitage, W C Fanslow, M K Spriggs, W J Murphy.   

Abstract

CD40 is a molecule present on B lymphocyte lineage cells that is important in B-cell differentiation and activation. Signaling through CD40 has been shown to exert costimulatory signals on normal B cells resulting in proliferative and differentiation responses. Examination of several B-cell lymphomas showed cell-surface expression of the CD40 molecule. Incubation of these lymphomas with anti-CD40 antibodies resulted in significant growth inhibition in vitro. Cross-linking of the CD40 antibodies resulted in even greater inhibition of proliferation. A recombinant soluble human CD40 ligand was also shown to inhibit lymphoma proliferation. When various human B-cell lymphomas were transferred into mice with severe combined immune deficiency, the treatment of the mice with anti-CD40 antibodies resulted in significant increases in survival showing that anti-CD40 is efficacious after in vivo administration. Thus, CD40 stimulation by either the antibody or soluble ligand directly inhibits human B-cell lymphoma growth and therefore, may be of significant clinical use in their treatment.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514045

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  Anatomy of a joint venture: Dana Farber/Partners Cancer Care.

Authors:  B A Chabner
Journal:  Trans Am Clin Climatol Assoc       Date:  1999

2.  Low-grade B cell lymphomas of mucosa-associated lymphoid tissue (MALT-type) require CD40-mediated signaling and Th2-type cytokines for in vitro growth and differentiation.

Authors:  A Greiner; C Knörr; Y Qin; W Sebald; A Schimpl; J Banchereau; H K Müller-Hermelink
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

3.  Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells.

Authors:  M A Ghetie; E M Podar; A Ilgen; B E Gordon; J W Uhr; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1997-07-08       Impact factor: 11.205

Review 4.  Molecular mechanism and function of CD40/CD40L engagement in the immune system.

Authors:  Raul Elgueta; Micah J Benson; Victor C de Vries; Anna Wasiuk; Yanxia Guo; Randolph J Noelle
Journal:  Immunol Rev       Date:  2009-05       Impact factor: 12.988

Review 5.  Growth and survival of B-chronic lymphocytic leukaemia cells.

Authors:  O Söderberg
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

Review 6.  Immunotherapy in pancreatic cancer treatment: a new frontier.

Authors:  Komal Thind; Leslie J Padrnos; Ramesh K Ramanathan; Mitesh J Borad
Journal:  Therap Adv Gastroenterol       Date:  2016-10-17       Impact factor: 4.409

7.  Inhibition of proliferation and induction of apoptosis in multiple myeloma cell lines by CD137 ligand signaling.

Authors:  Charles Gullo; Liang Kai Koh; Wan Lu Pang; Kian Tong Ho; Shi Hao Tan; Herbert Schwarz
Journal:  PLoS One       Date:  2010-05-26       Impact factor: 3.240

8.  CD40 induces antigen transporter and immunoproteasome gene expression in carcinomas via the coordinated action of NF-kappaB and of NF-kappaB-mediated de novo synthesis of IRF-1.

Authors:  Aristides Moschonas; Maria Kouraki; Pauline G Knox; Efstathia Thymiakou; Dimitris Kardassis; Aristides G Eliopoulos
Journal:  Mol Cell Biol       Date:  2008-08-11       Impact factor: 4.272

9.  Levels of CD40 expression on dendritic cells dictate tumour growth or regression.

Authors:  G Murugaiyan; S Martin; B Saha
Journal:  Clin Exp Immunol       Date:  2007-05-04       Impact factor: 4.330

10.  Tpl2 transduces CD40 and TNF signals that activate ERK and regulates IgE induction by CD40.

Authors:  Aristides G Eliopoulos; Chun-Chi Wang; Calin D Dumitru; Philip N Tsichlis
Journal:  EMBO J       Date:  2003-08-01       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.